Previous 10 | Next 10 |
Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity PR Newswire SAN DIEGO , Nov. 30, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development ...
Regulus Therapeutics (NASDAQ:RGLS) says it has entered into a private placement of equity with institutional investors led by Federated Hermes Kaufmann Funds and New Enterprise Associates. The company anticipates proceeds of $34.6M. The financing is expected to close on Nov. 30. SVB Leerink w...
Regulus Therapeutics Inc. (RGLS) Q3 2021 Earnings Conference Call November 10, 2021 17:00 ET Company Participants Cris Calsada - Chief Financial Officer Jay Hagan - President and Chief Executive Officer Denis Drygin - Chief Scientific Officer Conference Call Participants Brian Cheng - Cantor ...
Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates -Company advances RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)- -Validating sections of IND-enabling toxicity studies for RGLS8429 completed- -IND s...
OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...
Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , Nov. 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...
Are These Penny Stocks A Buy Or Avoid Right Now? If you’re like most retail traders right now, you’re on the hunt for the next round of hot penny stocks to buy. In the stock market today, meme stocks are heating up. What some may consider the “OG” or bell...
Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease -Company will advance RGLS8429 supported by strong preclinical data and superior pharmacologic profile as compared...
3 High Volume Biotech Penny Stocks to Watch in October 2021 Looking for biotech penny stocks with high volume is a great way to stay ahead in the stock market. Right now, there is a lot of momentum to take advantage of in the stock market. Because of the sheer number of factors impactin...
Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science PR Newswire SAN DIEGO , Sept. 30, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...